Piptavita 4.5 Injection

Piptavita 4.5 Injection contains Piperacillin 4 g + Tazobactam 0.5 g (as sterile powder for injection). Prescription required.

Treatment of susceptible bacterial infections such as hospital- or community-acquired pneumonia, complicated urinary tract infections, complicated intra-abdominal infections, skin and soft tissue infections, gynecological infections, and septicemia; also used in febrile neutropenia as per clinician advice.

Piperacillin is a broad-spectrum penicillin antibiotic that inhibits bacterial cell wall synthesis. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation, helping extend activity against beta-lactamase–producing organisms.

For intravenous use only. Reconstitute the vial with a compatible diluent and administer as IV injection/infusion as prescribed by a doctor; dose and duration depend on infection type, severity, kidney function and clinical response. May be given with or without food; complete the full course.

Diarrhea, nausea, vomiting, rash, injection site pain/phlebitis, headache, fever, elevated liver enzymes, low potassium (hypokalemia), thrombocytopenia/leukopenia (rare)

Prescription-only injectable antibiotic; use under medical supervision. Contraindicated in patients with known hypersensitivity to piperacillin/tazobactam, penicillins, cephalosporins or other beta-lactams; risk of severe allergic reactions. Dose adjustment needed in renal impairment; monitor kidney function, CBC and liver enzymes during prolonged therapy. Risk of Clostridioides difficile–associated diarrhea; seek care for severe/persistent diarrhea. Use with caution in patients with bleeding disorders or on anticoagulants (may affect coagulation tests).

Warfarin/other anticoagulants (increased bleeding risk/altered coagulation parameters), methotrexate (reduced clearance/increased toxicity), probenecid (increases levels), vancomycin (higher risk of kidney injury when combined), aminoglycosides (do not mix in same syringe/IV line; possible additive nephrotoxicity)

Store unopened vial at room temperature (generally below 25°C), protected from light and moisture. After reconstitution/dilution, use within the time limits recommended on the label/hospital protocol; do not freeze unless label permits.

Piptaz 4.5 Injection, Tazact 4.5 Injection, Pipzo 4.5 Injection, Zosyn 4.5 Injection, Tazopip 4.5 Injection